Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308347112> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W4308347112 endingPage "199" @default.
- W4308347112 startingPage "195" @default.
- W4308347112 abstract "Immunotherapy (IO)-based combinations used to treat metastatic clear cell renal cell carcinoma (ccRCC) include dual immune checkpoint inhibition with ipilimumab and nivolumab (IO/IO) and several combinations of vascular endothelial growth factor receptor-targeting tyrosine kinase inhibitors (TKIs) with an immune checkpoint inhibitor (TKI/IO). IO/IO and TKI/IO approaches have not been compared directly, and it is unknown whether patients who do not respond to first-line IO/IO can salvage long-term survival by receiving a second-line TKI. Progression-free survival after second-line therapy (PFS-2) evaluates the ability to be salvaged by second-line therapy. We retrospectively evaluated 173 patients treated with first-line IO/IO or TKI/IO for metastatic ccRCC at Memorial Sloan Kettering Cancer Center and report PFS-2, overall survival, and response to second line of therapy (ORR2nd) for groups defined by first-line category. Although ORR2nd was significantly higher with IO/IO than with TKI/IO (47% vs 13%, p < 0.001), there was no significant difference in median PFS-2 for TKI/IO versus IO/IO (44 vs 23 mo, log-rank p = 0.1) or restricted mean survival time (RMST) for PFS-2 when adjusted for propensity score (33 vs 30 mo; difference 2.6 mo [95% confidence interval {CI}: -2.6, 7.9]; p = 0.3). There was also no significant difference in RMST for overall survival when adjusted for propensity score (38 vs 37 mo; group difference 1.0 mo [95% CI: -3.4, 5.5]; p = 0.7). These findings do not support a change in current utilization practices for IO/IO and TKI/IO treatment strategies for ccRCC. PATIENT SUMMARY: In cases of metastatic clear cell renal cell carcinoma, no significant difference was observed in progression-free survival after second line of therapy between patients receiving ipilimumab plus nivolumab and those receiving a combination of a tyrosine kinase inhibitor and an immune checkpoint inhibitor." @default.
- W4308347112 created "2022-11-11" @default.
- W4308347112 creator A5018531384 @default.
- W4308347112 creator A5018855400 @default.
- W4308347112 creator A5019538697 @default.
- W4308347112 creator A5034814142 @default.
- W4308347112 creator A5035440326 @default.
- W4308347112 creator A5039091638 @default.
- W4308347112 creator A5049338175 @default.
- W4308347112 creator A5058692226 @default.
- W4308347112 creator A5059063118 @default.
- W4308347112 creator A5067522153 @default.
- W4308347112 creator A5073268337 @default.
- W4308347112 creator A5091859782 @default.
- W4308347112 date "2023-03-01" @default.
- W4308347112 modified "2023-10-17" @default.
- W4308347112 title "Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations" @default.
- W4308347112 cites W1991528069 @default.
- W4308347112 cites W2019607817 @default.
- W4308347112 cites W2036193982 @default.
- W4308347112 cites W2099752220 @default.
- W4308347112 cites W2792937256 @default.
- W4308347112 cites W2911812451 @default.
- W4308347112 cites W2913745075 @default.
- W4308347112 cites W3093923068 @default.
- W4308347112 cites W3107453141 @default.
- W4308347112 cites W3131063362 @default.
- W4308347112 cites W3134949580 @default.
- W4308347112 cites W3171692319 @default.
- W4308347112 cites W4226239716 @default.
- W4308347112 doi "https://doi.org/10.1016/j.eururo.2022.10.017" @default.
- W4308347112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36344318" @default.
- W4308347112 hasPublicationYear "2023" @default.
- W4308347112 type Work @default.
- W4308347112 citedByCount "1" @default.
- W4308347112 countsByYear W43083471122023 @default.
- W4308347112 crossrefType "journal-article" @default.
- W4308347112 hasAuthorship W4308347112A5018531384 @default.
- W4308347112 hasAuthorship W4308347112A5018855400 @default.
- W4308347112 hasAuthorship W4308347112A5019538697 @default.
- W4308347112 hasAuthorship W4308347112A5034814142 @default.
- W4308347112 hasAuthorship W4308347112A5035440326 @default.
- W4308347112 hasAuthorship W4308347112A5039091638 @default.
- W4308347112 hasAuthorship W4308347112A5049338175 @default.
- W4308347112 hasAuthorship W4308347112A5058692226 @default.
- W4308347112 hasAuthorship W4308347112A5059063118 @default.
- W4308347112 hasAuthorship W4308347112A5067522153 @default.
- W4308347112 hasAuthorship W4308347112A5073268337 @default.
- W4308347112 hasAuthorship W4308347112A5091859782 @default.
- W4308347112 hasBestOaLocation W43083471121 @default.
- W4308347112 hasConcept C121608353 @default.
- W4308347112 hasConcept C126322002 @default.
- W4308347112 hasConcept C143998085 @default.
- W4308347112 hasConcept C17923572 @default.
- W4308347112 hasConcept C2777472916 @default.
- W4308347112 hasConcept C2777701055 @default.
- W4308347112 hasConcept C2780030458 @default.
- W4308347112 hasConcept C2780739268 @default.
- W4308347112 hasConcept C2781433595 @default.
- W4308347112 hasConcept C3019894029 @default.
- W4308347112 hasConcept C44249647 @default.
- W4308347112 hasConcept C71924100 @default.
- W4308347112 hasConceptScore W4308347112C121608353 @default.
- W4308347112 hasConceptScore W4308347112C126322002 @default.
- W4308347112 hasConceptScore W4308347112C143998085 @default.
- W4308347112 hasConceptScore W4308347112C17923572 @default.
- W4308347112 hasConceptScore W4308347112C2777472916 @default.
- W4308347112 hasConceptScore W4308347112C2777701055 @default.
- W4308347112 hasConceptScore W4308347112C2780030458 @default.
- W4308347112 hasConceptScore W4308347112C2780739268 @default.
- W4308347112 hasConceptScore W4308347112C2781433595 @default.
- W4308347112 hasConceptScore W4308347112C3019894029 @default.
- W4308347112 hasConceptScore W4308347112C44249647 @default.
- W4308347112 hasConceptScore W4308347112C71924100 @default.
- W4308347112 hasIssue "3" @default.
- W4308347112 hasLocation W43083471121 @default.
- W4308347112 hasLocation W43083471122 @default.
- W4308347112 hasOpenAccess W4308347112 @default.
- W4308347112 hasPrimaryLocation W43083471121 @default.
- W4308347112 hasRelatedWork W2969738919 @default.
- W4308347112 hasRelatedWork W2971105467 @default.
- W4308347112 hasRelatedWork W3023368852 @default.
- W4308347112 hasRelatedWork W3096390161 @default.
- W4308347112 hasRelatedWork W3152520552 @default.
- W4308347112 hasRelatedWork W3216520672 @default.
- W4308347112 hasRelatedWork W3217213935 @default.
- W4308347112 hasRelatedWork W4210291640 @default.
- W4308347112 hasRelatedWork W4235771139 @default.
- W4308347112 hasRelatedWork W4295817599 @default.
- W4308347112 hasVolume "83" @default.
- W4308347112 isParatext "false" @default.
- W4308347112 isRetracted "false" @default.
- W4308347112 workType "article" @default.